{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:14Z","timestamp":1793502914651,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":77,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab however, results in high-turnover bone loss and increased fracture risk. The optimal way to prevent this bone loss remains undefined. This study is a preplanned extension of the DATA-HD study, where postmenopausal women with osteoporosis were randomized to receive 9\u2009months of either 20 \u03bcg or 40 \u03bcg of teriparatide daily overlapping with denosumab (60 mg administered at months 3 and 9). At the completion of this 15-month study, women were invited to enroll in the DATA-HD Extension where they received a single dose of zoledronic acid (5 mg) 24 to 35\u2009weeks after the last denosumab dose. Areal BMD and bone turnover markers were measured at month 27 and 42 (12 and 27\u2009months after zoledronic acid, respectively) and spine and hip volumetric bone density by quantitative CT was measured at month 42. Fifty-three women enrolled in the DATA-HD Extension. At the femoral neck and total hip, the mean 5.6% and 5.1% gains in BMD achieved from month 0 to 15 were maintained both 12 and 27\u2009months after zoledronic acid administration. At the spine, the mean 13.6% gain in BMD achieved from month 0 to 15 was maintained for the first 12\u2009months but modestly decreased thereafter, resulting in a 3.0% reduction (95% CI, \u22124.0% to \u22122.0%, p\u2009&amp;lt;\u2009.0001) 27\u2009months after zoledronic acid. The pattern of BMD changes between months 15 and 42 were qualitatively similar in the 20-\u03bcg and 40-\u03bcg groups. A single dose of zoledronic acid effectively maintains the large and rapid total hip and femoral neck BMD increases achieved with combination teriparatide\/denosumab therapy for at least 27\u2009months following the transition. Spine BMD was also largely, though not fully, maintained during this period. These data suggest that the DATA-HD Extension regimen may be an effective strategy in the long-term management of patients at high risk of fragility fracture. \u00a9 2021 American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4259","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T17:45:09Z","timestamp":1611855909000},"page":"921-930","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8469","authenticated-orcid":false,"given":"Sabashini K","family":"Ramchand","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrine Unit Austin Hospital, The University of Melbourne Heidelberg VIC Australia"},{"name":"Department of Medicine, Endocrine Unit Massachusetts General Hospital, Harvard University Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L","family":"David","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit Massachusetts General Hospital, Harvard University Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Center Massachusetts General Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Academic Unit of Bone Metabolism University of Sheffield Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy N","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit Massachusetts General Hospital, Harvard University Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit Massachusetts General Hospital, Harvard University Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"issue":"8","key":"2024012713505594800_jbmr4259-bib-0001","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024012713505594800_jbmr4259-bib-0002","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024012713505594800_jbmr4259-bib-0003","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2024012713505594800_jbmr4259-bib-0004","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"4","key":"2024012713505594800_jbmr4259-bib-0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","article-title":"Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo(R) Observational Study (ExFOS)","volume":"103","author":"Napoli","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"2024012713505594800_jbmr4259-bib-0006","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024012713505594800_jbmr4259-bib-0007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024012713505594800_jbmr4259-bib-0008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"2024012713505594800_jbmr4259-bib-0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"issue":"10","key":"2024012713505594800_jbmr4259-bib-0010","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024012713505594800_jbmr4259-bib-0011","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024012713505594800_jbmr4259-bib-0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2024012713505594800_jbmr4259-bib-0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00223-019-00553-w","article-title":"Effect of zoledronate on bone loss after romosozumab\/denosumab: 2-year follow-up","volume":"105","author":"Horne","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2024012713505594800_jbmr4259-bib-0014","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2024012713505594800_jbmr4259-bib-0015","doi-asserted-by":"crossref","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"138","author":"Makras","year":"2020","journal-title":"Bone"},{"issue":"7","key":"2024012713505594800_jbmr4259-bib-0016","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024012713505594800_jbmr4259-bib-0017","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024012713505594800_jbmr4259-bib-0018","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024012713505594800_jbmr4259-bib-0019","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","volume":"7","author":"Tsai","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2024012713505594800_jbmr4259-bib-0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024012713505594800_jbmr4259-bib-0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024012713505594800_jbmr4259-bib-0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jbmr.506","article-title":"Simulated increases in body fat and errors in bone mineral density measurements by DXA and QCT","volume":"27","author":"Yu","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024012713505594800_jbmr4259-bib-0023","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/02841850510012661","article-title":"Effect of spinal degenerative changes on volumetric bone mineral density of the central skeleton as measured by quantitative computed tomography","volume":"46","author":"Guglielmi","year":"2005","journal-title":"Acta Radiol"},{"issue":"2","key":"2024012713505594800_jbmr4259-bib-0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/JCD:2:2:181","article-title":"Aortic calcification contributing to bone densitometry measurement","volume":"2","author":"Smith","year":"1999","journal-title":"J Clin Densitom"},{"issue":"6","key":"2024012713505594800_jbmr4259-bib-0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF02652563","article-title":"Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women","volume":"7","author":"Liu","year":"1997","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024012713505594800_jbmr4259-bib-0026","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024012713505594800_jbmr4259-bib-0027","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024012713505594800_jbmr4259-bib-0028","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1359\/jbmr.1997.12.8.1152","article-title":"Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis","volume":"12","author":"Dempster","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024012713505594800_jbmr4259-bib-0029","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"key":"2024012713505594800_jbmr4259-bib-0030","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep"},{"issue":"3","key":"2024012713505594800_jbmr4259-bib-0031","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/5\/921\/56289747\/jbmr4259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/5\/921\/56289747\/jbmr4259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:06:49Z","timestamp":1710328009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/5\/921-930\/7516887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4259","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4259\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4259\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}